Shlomchik Warren D
Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO BOX 208032, New Haven, Connecticut 06520, USA.
Nat Rev Immunol. 2007 May;7(5):340-52. doi: 10.1038/nri2000.
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alphabeta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient. Unfortunately, these T cells recognize the recipient as 'non-self' and employ a wide range of immune mechanisms to attack recipient tissues in a process known as graft-versus-host disease (GVHD). The full therapeutic potential of allogeneic haematopoietic SCT will not be realized until approaches to minimize GVHD, while maintaining the positive contributions of donor T cells, are developed. This Review focuses on research in mouse models pursued to achieve this goal.
异基因造血干细胞移植（SCT）是治疗血液系统恶性肿瘤和遗传性血细胞疾病（如镰状细胞贫血）的一种治愈性疗法。移植的同种异体移植物中所含的成熟αβ T细胞可重建T细胞免疫，并能根除受体中的恶性细胞。不幸的是，这些T细胞将受体识别为“非自身”，并在一个称为移植物抗宿主病（GVHD）的过程中采用多种免疫机制攻击受体组织。在开发出在维持供体T细胞积极作用的同时尽量减少GVHD的方法之前，异基因造血SCT的全部治疗潜力将无法实现。本综述重点关注为实现这一目标而在小鼠模型中开展的研究。
